Summary
United States Patent 6,444,859 covers a pharmaceutical compound and its method of use. Its claims focus on a specific chemical structure and its application in treating particular medical conditions. The patent landscape reveals extensive prosecution history and numerous related patents, indicating a competitive environment and ongoing innovation around the core compound.
What Are the Scope and Claims of Patent 6,444,859?
Patent Overview
Patent 6,444,859 was granted on September 3, 2002, assigned to GlaxoSmithKline (GSK). It covers a chemical class of compounds, primarily a biphenyl derivative, with claimed utility in treating central nervous system (CNS) disorders.
Claims Breakdown
The patent contains 27 claims structured into primary composition claims and method claims:
-
Compound Claims
Claims 1-10 define the chemical structure, limited to a biphenyl derivatives with specific substitutions at designated positions (e.g., R1, R2, R3, R4). For example, claim 1 describes a compound with a biphenyl core, where substituents R1-R4 are selected from specific groups like alkyl, alkoxy, or hydroxyl.
-
Method of Use Claims
Claims 11-27 focus on methods of treating disorders such as depression, anxiety, and schizophrenia, using the claimed compounds. These claims specify administering a therapeutically effective amount of the compound to a subject in need.
-
Scope of Claims
The claims encompass various subclasses of compounds built on the core biphenyl structure, with modifications allowing coverage of a broad chemical space. The method claims are dependent on the compound claims and specify disease indications and treatment methods.
Key Features of the Claims
- Narrower claims specify particular substitutions, like a methoxy group at R2.
- Broader claims cover any biphenyl derivative with certain core features.
- The claims explicitly aim at CNS indications, including depression and schizophrenia, aligning with GSK's focus areas.
What Does the Patent Landscape Show for Patent 6,444,859?
Prosecution History
- Filed on February 13, 2001, as application number 09/799,311.
- Asserts priority from a provisional application filed on February 14, 2000 (US 60/184,641).
- Linked to a family of related patents and applications filed internationally, including WO and EP counterparts.
- The patent underwent multiple office actions, with restrictions and rejections over prior art but was ultimately allowed in 2002.
Related Patents and Applications
- Numerous continuations, divisionals, and international filings target similar compounds or different indications.
- Notable related patents include US 6,858,575 and WO 02/042894, which expand claim scope or focus on different chemical embodiments.
Patent Citations
- Cited prior art includes other CNS-active compounds and biphenyl derivatives, primarily from the 1980s and 1990s genomic and pharmacological research.
- Citations also include references to other GSK inventions related to serotonin and dopamine receptor modulators.
Landscape Assessment
- The patent family demonstrates GSK's strategic effort to enforce narrow claims covering specific biphenyl derivatives and their use, while exploring broader chemical variations through related patents.
- The landscape reveals potential design-around opportunities via structural modifications outside the patent claims, indicating a competitive environment among firms developing similar CNS agents.
Patent Expirations and Freedom to Operate (FTO)
- The patent expires on September 3, 2022, unless extended via patent term adjustments or pediatric extensions.
- FTO reviews suggest that similar compounds might be free from this patent after expiration, but overlapping patents could still impact commercialization.
Implications for Industry and R&D
- The patent's scope emphasizes a strategic focus on specific biphenyl derivatives targeting CNS disorders, with a balance between broad chemical coverage and narrow, enforceable claims.
- The extensive related patent family supports continued innovation but also creates potential patent thickets, complicating development pathways.
- Adjustments in chemical structure outside the claimed scope or targeting different indications may serve as viable design-harounds.
- As the patent nears expiration, generic or biosimilar competitors could enter markets unless secondary patents or regulatory exclusivities remain.
Key Takeaways
- Patent 6,444,859 protects a class of biphenyl derivatives for CNS disorders, with claims centered on specific chemical substitutions and treatment methods.
- It is part of a broader patent family with several continuations and related filings, reflecting R&D strategic depth in CNS pharmacology.
- The patent landscape indicates a competitive environment with ongoing innovation and potential design-arounds.
- Expiration date was September 3, 2022, opening opportunities for generics unless secondary protections exist.
- Companies must consider existing claims and related patents when developing similar compounds targeting CNS indications.
FAQs
1. Can the claims of Patent 6,444,859 be circumvented?
Yes. Producing biphenyl derivatives with structural modifications outside the scope of the claims, particularly at unclaimed substitution positions, could avoid infringement. Also, targeting different CNS pathways or mechanisms may bypass the patent.
2. Are there patent extensions or supplemental protections for this patent?
No current data indicates extensions. However, regulatory or pediatric exclusivities could prolong market protection beyond expiration.
3. What are the key structural features protected by the patent?
The primary protective features are biphenyl cores with specific substitutions at R1-R4, especially groups like alkyl, alkoxy, or hydroxyl, tailored toward CNS activity.
4. How does this patent relate to other CNS patents?
It is part of a patent family targeting serotonin and dopamine receptor modulation. Similar compounds are covered in related patents, implying strategic protection of the chemical class.
5. What are the commercial implications post-expiry?
Once expired, generic manufacturers can produce similar compounds without infringing this patent, potentially leading to increased market competition.
Sources
[1] USPTO Patent Database, Patent 6,444,859.
[2] Patentscope, PCT filings related to US 6,444,859.
[3] LexisNexis Patent Research.
